The drug, known as Dz13, specifically targets and neutralises the gene responsible for inflammation and muscle death in the aftermath of a heart attack, preclinical trials have found.
The drug also reduces incidental cell and tissue death resulting from life-saving interventions such as balloon angioplasty and stent placements used to open blocked arteries, or from the delivery of clot-busting drugs.
Significantly, the heart
Latest Articles
The drug, known as Dz13, specifically targets and neutralises the gene responsible for inflammation and muscle death in the aftermath of a heart attack,...
